drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific monoclonal antibody)
drug_description
A subcutaneous BCMA×CD3 bispecific IgG T-cell–engaging antibody that binds BCMA on malignant plasma cells and CD3 on T cells to form an immune synapse, activate T cells, and kill BCMA-positive myeloma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Elranatamab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Elranatamab is a BCMA×CD3 bispecific IgG antibody that binds BCMA on myeloma/plasma cells and CD3 on T cells, forming an immune synapse to activate and redirect T‑cell cytotoxicity and cytokine release, leading to lysis of BCMA‑positive myeloma cells.
drug_name
Elranatamab (PF-06863135)
nct_id_drug_ref
NCT06282978